BTIG analyst Thomas Shrader has maintained their bullish stance on ALEC stock, giving a Buy rating on September 23.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader has given his Buy rating due to a combination of factors that highlight Alector’s strategic positioning in the competitive field of neuroscience. Alector’s innovative approach with their Alector Brain Carrier (ABC) technology demonstrates a significant advancement in the delivery of therapeutics across the blood-brain barrier, which is crucial for treating neurological conditions effectively. The company’s detailed data on TfR-receptor affinities and their ability to target novel domains suggest a strong potential for successful preclinical development, as these domains are conserved in non-human primates and likely protectable.
Alector’s focus on well-validated targets such as Tau for Alzheimer’s disease and aSyn for Parkinson’s disease further strengthens their pipeline, indicating a strategic approach to addressing major neurological disorders. The company’s protein engineering capabilities were showcased, suggesting that their therapeutics will be optimized based on current animal models. Additionally, the potential of their GCase enzyme for Parkinson’s and Gaucher’s disease, with improved CNS penetration and systemic uptake, adds to the optimism. The valuation of Alector using a discounted cash flow analysis supports the Buy rating, reflecting confidence in the company’s future growth prospects.
In another report released on September 23, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
ALEC’s price has also changed dramatically for the past six months – from $1.370 to $3.160, which is a 130.66% increase.